Difficulty: Medium
Average Score: 73%
Practice
Which of the following drugs is an inhibitor of platelet glycoprotein IIb/IIIa receptors?
Correct answer
D
Rationale
The correct answer is D) Abciximab. Abciximab is an inhibitor of platelet glycoprotein IIb/IIIa receptors, which are crucial for platelet aggregation. Abciximab works by blocking these receptors, preventing platelets from clumping together and reducing the risk of blood clot formation.
Option A) Aspirin is a cyclooxygenase inhibitor that inhibits platelet aggregation by blocking thromboxane formation, not by directly inhibiting glycoprotein IIb/IIIa receptors.
Option B) Clopidogrel and Option C) Ticlopidine are both antiplatelet drugs that work by inhibiting platelet activation through other mechanisms, not by directly targeting glycoprotein IIb/IIIa receptors.
In an educational context, understanding the mechanisms of action of different antiplatelet drugs is crucial for healthcare professionals in managing patients with cardiovascular diseases. Knowing which drugs target specific receptors or pathways helps in selecting the most appropriate therapy based on individual patient characteristics and conditions to optimize treatment outcomes and minimize adverse effects.
Option A) Aspirin is a cyclooxygenase inhibitor that inhibits platelet aggregation by blocking thromboxane formation, not by directly inhibiting glycoprotein IIb/IIIa receptors.
Option B) Clopidogrel and Option C) Ticlopidine are both antiplatelet drugs that work by inhibiting platelet activation through other mechanisms, not by directly targeting glycoprotein IIb/IIIa receptors.
In an educational context, understanding the mechanisms of action of different antiplatelet drugs is crucial for healthcare professionals in managing patients with cardiovascular diseases. Knowing which drugs target specific receptors or pathways helps in selecting the most appropriate therapy based on individual patient characteristics and conditions to optimize treatment outcomes and minimize adverse effects.